Axonics® launches artistry study to collect and analyze real-world data of patients implanted with the axonics r-snm system

Irvine, calif.--(business wire)--axonics modulation technologies, inc. (nasdaq: axnx), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (snm) devices for the treatment of urinary and bowel dysfunction, has launched a new post-market clinical registry study to collect and analyze real-world data of patients treated with the axonics r-snm® system. the axonics sacral neuromodulation system registry (artistry), a prospective, multicente
AXNX Ratings Summary
AXNX Quant Ranking